Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Front Immunol. 2023 May 8;14:1175348. doi: 10.3389/fimmu.2023.1175348. eCollection 2023.
Type I interferons (IFNs) are highly expressed in the gut mucosa of celiac disease (CD) gut mucosa and stimulates immune response prompted by gluten ingestion, but the processes that maintain the production of these inflammatory molecules are not well understood. Adenosine deaminase acting on RNA 1 (ADAR1), an RNA-editing enzyme, plays a crucial role in inhibiting self or viral RNAs from activating auto-immune mediated responses, most notably within the type-I IFN production pathway. The aim of this study was to assess whether ADAR1 could contribute to the induction and/or progression of gut inflammation in patients with celiac disease.
ADAR1 expression was assessed by Real time PCR and Western blotting in duodenal biopsy taken from inactive and active celiac disease (CD) patients and normal controls (CTR). To analyze the role of ADAR1 in inflamed CD mucosa, lamina propria mononuclear cells (LPMC) were isolated from inactive CD and ADAR1 was silenced in with a specific antisense oligonucleotide (AS) and then incubated with a synthetic analogue of viral dsRNA (poly I:C). IFN-inducing pathways (IRF3, IRF7) in these cells were evaluated with Western blotting and inflammatory cytokines were evaluated with flow cytometry. Lastly, the role of ADAR1 was investigated in a mouse model of poly I:C-driven small intestine atrophy.
Reduced ADAR1 expression was seen in duodenal biopsies compared to inactive CD and normal controls. organ cultures of duodenal mucosal biopsies, taken from inactive CD patients, stimulated with a peptic-tryptic digest of gliadin displayed a decreased expression of ADAR1. ADAR1 silencing in LPMC stimulated with a synthetic analogue of viral dsRNA strongly boosted the activation of IRF3 and IRF7 and the production of type-I IFN, TNF-α and IFN-γ. Administration of ADAR1 antisense but not sense oligonucleotide to mice with poly I:C-induced intestinal atrophy, significantly increased gut damage and inflammatory cytokines production.
These data show that ADAR1 is an important regulator of intestinal immune homeostasis and demonstrate that defective ADAR1 expression could provide to amplifying pathogenic responses in CD intestinal mucosa.
I 型干扰素(IFNs)在乳糜泻(CD)肠黏膜中高度表达,并刺激由麸质摄入引起的免疫反应,但维持这些炎症分子产生的过程尚不清楚。腺苷脱氨酶作用于 RNA 1(ADAR1)是一种 RNA 编辑酶,在抑制自身或病毒 RNA 激活自身免疫介导的反应中发挥关键作用,尤其是在 I 型 IFN 产生途径中。本研究旨在评估 ADAR1 是否有助于诱导和/或进展乳糜泻患者的肠道炎症。
通过实时 PCR 和 Western blot 评估来自活动性和非活动性乳糜泻(CD)患者和正常对照(CTR)的十二指肠活检中的 ADAR1 表达。为了分析 ADAR1 在炎症性 CD 黏膜中的作用,从非活动性 CD 中分离出黏膜固有层单核细胞(LPMC),并用特异性反义寡核苷酸(AS)沉默 ADAR1,然后用合成的病毒 dsRNA 类似物(poly I:C)孵育。用 Western blot 评估这些细胞中的 IFN 诱导途径(IRF3、IRF7),并用流式细胞术评估炎症细胞因子。最后,在聚 I:C 驱动的小肠萎缩小鼠模型中研究了 ADAR1 的作用。
与非活动性 CD 和正常对照相比,十二指肠活检中 ADAR1 的表达减少。来自非活动性 CD 患者的十二指肠黏膜活检的器官培养物,用肽酶消化的麦胶刺激,显示 ADAR1 的表达降低。用合成的病毒 dsRNA 类似物刺激时,LPMC 中的 ADAR1 沉默强烈增强了 IRF3 和 IRF7 的激活以及 I 型 IFN、TNF-α 和 IFN-γ 的产生。用聚 I:C 诱导的肠道萎缩小鼠给予 ADAR1 反义但不是 sense 寡核苷酸,显著增加了肠道损伤和炎症细胞因子的产生。
这些数据表明 ADAR1 是肠道免疫稳态的重要调节剂,并表明 ADAR1 表达缺陷可能为 CD 肠道黏膜中的致病性反应提供放大作用。